Novel 2009 Influenza A (H1N1) Infection
Conditions
Keywords
H1N1 2009, hyperimmune IVIG, mortality, length of stay, viral load, cytokine
Brief summary
Treatment with hyperimmune intravenous immunoglobulin (H-IVIG), derived from convalescent plasma from patients recovered from H1N1 2009 influenza A infection, for patients with severe H1N1 2009 infection will decrease mortality, reduce viral load, and shorten the length of stay in ICU and hospital.
Detailed description
Since the emergence of the novel swine origin influenza A virus (H1N1 2009) in Mexico in March 2009, the virus has led to a pandemic in over 170 countries, resulting in over 180 thousands microbiologically confirmed cases and over 18000 mortality. This strain represents a quadruple re-assortment of two swine strains, one human strain, and one avian strain of influenza. Although the H1N1 2009 is causing a mild disease and has a relatively low mortality rate currently in Hong Kong, severe cases have been reported. Patients infected with severe H1N1 2009 have overwhelmed the intensive care services in these countries and the mortality has rose up to 6% in Argentina and Brazil, and 0.4% in Australia. This is very much higher than the 0.06% mortality rate of the seasonal flu. Furthermore, there were reports of H1N1 2009 oseltamivir resistance and zanamivir is difficult to be delivered to the consolidated lungs in the severe cases when such drug is most needed. In Hong Kong, vaccination for the H1N1 2009 was prioritised to the older people aged 65 or above with chronic illness, younger people with chronic illness and health care workers. The healthy adults aged 18 to 65, who are most at risk of developing severe H1N1 2009 was not covered by the vaccination program. Experience from 1918 H1N1 pandemic and single case report on the treatment for severe H5N1 infection (Zhou et al. 2007) showed that hyperimmune convalescent plasma is useful (Luke et al. 2006). Mice experiments also showed that antibody therapy is highly effective in the case of H5N1 infection (Heltzer ML et al. 2009, Writing Committee of the Second World Heath Organization, 2008). Therefore, convalescent plasma from patients recovered from H1N1 2009 infection can be harvested to prepare for hyperimmune intravenous immunoglobulin (H-IVIG) and the prepared H-IVIG can be assessed in a randomised controlled trial for treatment of patients with severe H1N1 2009 infection.
Interventions
DRUGHyperimmune intravenous immunoglobulin
Single intravenous infusion of 0.4g/kg of H1N1 2009 H-IVIG
DRUGIntravenous immunoglobulin
Single intravenous infusion of 0.4g/kg of simple IVIG
Sponsors
Queen Mary Hospital, Hong Kong
Pamela Youde Nethersole Eastern Hospital
Ruttonjee Hospital, Hong Kong
United Christian Hospital
Queen Elizabeth Hospital, Hong Kong
Caritas Medical Centre, Hong Kong
HK Red Cross Blood Transfusion Service, Hong Kong
Research Fund for the Control of Infectious Diseases, Hong Kong
The University of Hong Kong
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* (fulfill all criteria): male or female patients 18 years or older * written informed consent by patient or next of kin (if patients too ill) * diagnosis of H1N1 2009 infection satisfying both clinical and laboratory criteria: 1. Laboratory criteria: at least one RT-PCR positive for H1N1 2009 from one of the clinical specimens (NPA, ETA, blood, urine or stool). 2. Clinical criteria: patients admitted to ICU with severe community acquired pneumonia as defined by a CURB-65 score of 3 or more * deterioration during treatment with optimal antiviral (oral or inhaler agents only) and typical and atypical antimicrobial coverage * required ICU and ventilatory support and within 7 days onset of symptoms.
Exclusion criteria
* age below 18 years * known hypersensitivity to immune globulin or any components of the formulation * known IgA deficiency * acquire the H1N1 2009 infection from health care facility * moribund patients or refusal of informed consent.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mortality | From date of randomization until the date of death from any cause during hospitalization, assessed up to 6 months |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse events | From date of randomization until the date of first documented adverse events due to treatment, assessed up to 1 week | To assess the safety of H-IVIG and IVIG treatment |
| ICU length of stay | Participants will be followed for the duration of ICU stay, an expected average of 4 weeks | — |
| Hospital length of stay | Participants will be followed for the duration of hospital stay, an expected average of 12 weeks | — |
| Nasopharyngeal viral load | One day before randomization and up to 5 days after treatment | To assess the change in nasopharyngeal viral load one day before randomization and 5 days after treatment |
| Cytokine/ chemokine | One day before randomization and up to 5 days after treatment | To assess the change in cytokine/ chemokine response one day before randomization and 5 days after treatment |
Countries
Hong Kong
Outcome results
None listed